Based on the above-mentioned results, we suggest that PRFR could decrease the level of expression of survival and metastasis proteins by the inhibition of AP-1 and NF-κB activation and are also in agreement with inhibition of AP-1 and NF-κB by epigallocatechin gallate reduced cancer cells survival and metastasis [38,39]. The gene discussed is NFKB1; the disease is cancer.